[1]程冬敏,吴保鑫,马正磊,等.美金刚对帕金森病痴呆患者生活质量的影响[J].卒中与神经疾病杂志,2016,23(06):429-432.[doi:10.3969/j.issn.1007-0478.2016.06.011]
　Cheng Dongmin,Wu Baoxin,Ma Zhenglei,et al.Effect of memantine on quality of life in patients with Parkinson disease dementia[J].Stroke and Nervous Diseases,2016,23(06):429-432.[doi:10.3969/j.issn.1007-0478.2016.06.011]
点击复制

美金刚对帕金森病痴呆患者生活质量的影响()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第23卷
期数:
2016年06期
页码:
429-432
栏目:
论 著
出版日期:
2016-12-30

文章信息/Info

Title:
Effect of memantine on quality of life in patients with Parkinson disease dementia
文章编号:
1007-0478(2016)06-0429-04
作者:
程冬敏; 吴保鑫; 马正磊; 王妍; 石彦彦; 张孝良
221600 江苏省徐州市沛县人民医院神经内科
Author(s):
Cheng Dongmin; Wu Baoxin; Ma Zhenglei; et al.
Department of Neurology, the Peoples' Hospital of Peixian, Xuzhou 221600
关键词:
帕金森痴呆 美金刚 生活质量
Keywords:
Parkinson disease dementia Memantine Quality of life.
分类号:
R742.5
DOI:
10.3969/j.issn.1007-0478.2016.06.011
文献标志码:
A
摘要:
目的 评估美金刚对帕金森病痴呆(PDD)患者生活质量的影响。方法 对45例帕金森病痴呆患者采用随机对照试验,评估美金刚治疗6个月后对其生活质量的影响; 通过目标实现缩放(Goal Attainment Scaling, GAS)、帕金森病问卷-8(Parkinson's Disease Questionnaire-8, PDQ-8),Zarit负担量表(Zarit Burden Interview, ZBI)评价患者的生活质量及照料者的负担。结果 治疗6个月后和对照组相比,试验组PDQ-8的改变没有显著差异(P>0.05),但试验组美金刚治疗后平均GAS分数和照顾者负担评分均显著改善(P分别为0.02和0.03)。结论 美金刚可以帮助患者实现更有临床意义的目标并减轻照顾者的负担。
Abstract:
ObjectiveTo evaluate the effect of memantine on the quality of life in Patients with Parkinson disease dementia(PDD).Methods After memantine treatment for 6 months, the quality of life of 45 patients with Parkinson disease dementia was evaluated by randomized contronlled trial.And the evaluation methods including Goal Attainment Scaling(GAS), the Parkinson's Disease Questionnaire-8(PDQ-8)and Zarit Burden Inventory(ZBI).Results After memantine treatment for 6 months,there is no significant difference in the PDQ-8 change between the experimental group and the control group(P>0.05); however,the GAS scales and the ZBI scales improved distinctly in the experimental group(p=0.02 and 0.03, respectively).Conclusion In this research,memantine treatment contributes to attaining clinically meaningful goals and ligthening the burden of the caregiver.

参考文献/References:

[1] Johansen KK,White LR,Sando SB,et al.Biomarkers: parkinson disease with dementia and dementia with Lewy bodies[J].Parkinsonism Relat Disord,2010,16(5):307-315.
[2] Leroi I,Mcdonald K,Pantula H,et al.Cognitive impairment in Parkinson disease: impact on quality of Life, disability, and caregiver burden[J].J Geriatr Psychiatry Neurol,2012,25(4):208-214.
[3] Olin JT,Schneider LS,Doody RS,et al.Clinical evaluation of global change in Alzheimer's disease: identifying consensus[J].J Geriatr Psychiatry Neurol,1996,9(4):176-180.
[4] Sampaio C.Clinical relevance on Alzheimer's disease endpoints[J].J Nutr Health Aging,2007,11(4):316-317.
[5] Rockwood K,Stolee P,Howard K,et al.Use of goal attainment scaling to measure treatment effects in an anti-dementia drug trial[J].Neuroepidemiology,1996,15(6):330-338.
[6] Emre M,Tsolaki M,Bonuccelli U,et al.Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial[J].Lancet Neurol,2010,9(10):969-977.
[7] Rockwood K,Stolee P,Howard K,et al.Use of goal attainment scaling to measure treatment effects in an anti-dementia drug trial[J].Neuroepidemiology,1996,15(6):330-338.
[8] Anon.Katsarou Z,bostantjopoulou S,Peto V,et al.Assessing quality of life in Parkinson's disease:can a short-from questionnaire be useful?[J].Mov Disord,2004,19(3):308-312.
[9] Santos-García D,Añón MJ,Fuster-Sanjurjo L,et al.Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson's diseaseleads to improvement in caregivers'stress and burden[J].Eur J Neurol,2012,19(9):1261-1265.
[10] Emre M,Aarsland D,Brown R,et al.Clinical diagnostic criteria for dementia associated with Parkinson's disease[J].Movement Disorders,2007,22(12):1689-1707.
[11] Gibb WR.Lees AJ.the relevance of the Lewy body to the pathogenesis of idiopathic parkinson's disease[J].J Neurol Neruosurg Psychiatry,1988,51(6):745-752.
[12] Kasten M,Bruggemann N,Schmidt A,et al.Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease[J].Neurology,2010,75(5):478; author reply 478-479.
[13] Möller HJ.Methodological aspects in the assessment of severity of depression by the Hamilton DepressionScale[J].Eur Arch Psychiatry Clin Neurosci,2001,251(12):13-20.
[14] Farlow MR,Graham SM,Alva G.Memantine for the treatment of Alzheimer s disease:tolerability and safety date from clinical trials[Z],2008:577.
[15] Sonkusare SK,Kaul CL,Ramarao P.Dementia of alzheimer's disease and other neurodegenerative disorders--memantine, a new hope[J].Pharmacol Res,2005,51(1):1-17.
[16] Rockwood K,Fay S,Gorman M,et al.The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial[Z],2007:26.
[17] Larsson V,Engedal K,Aarsland D,et al.Quality of Life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia[J].Dement Geriatr Cogn Disord,2011,32(4):227-234.

更新日期/Last Update: 2016-12-20